Australia's Cyclopharm rises on US FDA approval for lung treatment product

Cyclopharm

05/12/2023 01:34

** Shares of Cyclopharm  CYC.AX  rise as much as 3% to
A$2.060, set for best day since Nov. 24, if gains hold     
    ** Health technology co says it signed the first commercial
contract for the use of its Technegas product in the United
States
    ** Technegas used for treatment of asthma, pulmonary
hypertension, Long COVID, etc, has been approved by the U.S.
Food and Drug Administration - co
    ** Stock at highest level since Nov. 30
    ** 152,942 shares change hands, compared with the 30-day
average volume of 23,121
    ** CYC up 70.9% YTD as of last close

 (Reporting by Adwitiya Srivastava in Bengaluru)
 ((Adwitiya.Srivastava@thomsonreuters.com;))